News
Press Releases
-
May 10, 2023
Genesis Drug Discovery & Development (GD3), a member of Genesis Global Group, acquires JSS Medical Research to expand its clinical services portfolio.
View -
January 10, 2023
Genesis Axis Acquires Organochem to Grow the Preclinical Chemistry Services Portfolio.
View -
October 7, 2021
Genesis Biotechnology Group Acquires BioBlocks to Grow the Preclinical Chemistry Services Portfolio of Genesis Drug Discovery & Development (GD3)
View -
September 16, 2021
Genesis Drug Discovery & Development Appoints Anthony Rohr as Chief Operating Officer
View -
September 16, 2021
Genesis Drug Discovery & Development Appoints Laura Sailor Veteran CRO Business Development Leader as Director of Business Development
View -
March 4, 2021
Genesis Drug Discovery and Development acquires Integrated Analytical Solutions to add "off the shelf" PK profiling capabilities to its portfolio.
View -
January 6, 2021
Genesis Drug Discovery and Development expands its presence in the clinical space by acquiring STATKING Clinical Services
View -
December 9, 2020
Genesis Biotechnology Group announces second year of CRO relationship with Yale University
View -
August 5, 2020
Genesis Biotechnology Group acquires Comparative Biosciences, Inc. (CBI) to add GLP Toxicology and Safety Pharmacology to its portfolio of Preclinical Services
View -
August 4, 2020
Genesis Drug Discovery & Development (GD3) Announces Appointment of Anthony Rohr, as Chief Executive Officer of PharmOptima.
View -
November 19, 2019
Genesis Biotechnology Group acquires NEDP to grow the Preclinical Chemistry services portfolio of Genesis Drug Discovery & Development
View -
June 18, 2019
Genesis Drug Discovery & Development Expands Preclinical Contract Research Portfolio by Acquiring NexusPharma.
View -
January 1, 2016
EPO Berlin-Buch GmbH announces strategic partnership for the American market: EPO starts strategic collaboration with NexusPharma to foster its market position in the USA
View